Palvella Therapeutics (NASDAQ:PVLA) Trading 3.9% Higher – Here’s What Happened

Palvella Therapeutics, Inc. (NASDAQ:PVLA)’s stock price was up 3.9% during mid-day trading on Wednesday . The company traded as high as $104.20 and last traded at $103.75. Approximately 219,405 shares were traded during mid-day trading, an increase of 57% from the average daily volume of 139,882 shares. The stock had previously closed at $99.88.

Analyst Upgrades and Downgrades

PVLA has been the subject of several research analyst reports. UBS Group reiterated a “buy” rating and issued a $143.00 price objective on shares of Palvella Therapeutics in a research report on Monday, December 15th. TD Cowen upped their price objective on Palvella Therapeutics from $97.00 to $133.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Chardan Capital boosted their price objective on Palvella Therapeutics from $110.00 to $174.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Craig Hallum began coverage on shares of Palvella Therapeutics in a research report on Thursday, December 4th. They set a “buy” rating and a $175.00 target price for the company. Finally, Stifel Nicolaus lifted their price objective on Palvella Therapeutics from $87.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, November 24th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $155.60.

Palvella Therapeutics Stock Up 4.3%

The company has a market capitalization of $1.23 billion, a P/E ratio of -39.60 and a beta of -0.20. The firm has a fifty day simple moving average of $89.80 and a 200-day simple moving average of $61.49.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.18). On average, sell-side analysts predict that Palvella Therapeutics, Inc. will post -3.69 earnings per share for the current fiscal year.

Insider Activity at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $96.47, for a total value of $415,013.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 20.50% of the stock is currently owned by insiders.

Institutional Trading of Palvella Therapeutics

Institutional investors have recently modified their holdings of the company. Frazier Life Sciences Management L.P. lifted its position in shares of Palvella Therapeutics by 4.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock worth $16,283,000 after purchasing an additional 32,388 shares in the last quarter. Clio Asset Management LLC bought a new stake in Palvella Therapeutics during the 2nd quarter worth about $2,063,000. XTX Topco Ltd acquired a new position in shares of Palvella Therapeutics during the 2nd quarter worth about $399,000. Woodline Partners LP bought a new position in shares of Palvella Therapeutics in the 1st quarter valued at about $5,435,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Palvella Therapeutics in the first quarter valued at about $533,000. 40.11% of the stock is currently owned by institutional investors.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.